Gilead Made Gains In Oncology, Though Virology Remains King

New Studies And Catalysts For Trodelvy And Magrolimab Anticipated In 2021

 
• By Alaric DeArment
Digital illustration of Cancer cell in colour background
Gilead has made significant strides in developing its oncology business. • Source: Shutterstock

More from Business

More from Scrip